In:
Movement Disorders, Wiley, Vol. 19, No. 12 ( 2004-12), p. 1516-1518
Abstract:
To evaluate the efficacy of rivastigmine on motor and cognitive impairment in Huntington's disease (HD), we carried out a prospective, open‐label, randomized, controlled study. Twenty‐one HD patients were enrolled: 14 were randomly sorted into medication and 7 to no‐treatment groups. Clinical and demographic features were similar between groups. After 8 months, an efficacy evaluation was carried out to compare the two groups. The improvement of cholinergic transmission in HD patients seemed to have a slight effect in ameliorating cognitive performance and slowing motor deterioration. © 2004 Movement Disorder Society
Type of Medium:
Online Resource
ISSN:
0885-3185
,
1531-8257
Language:
English
Publisher:
Wiley
Publication Date:
2004
detail.hit.zdb_id:
2041249-6
Permalink